CT-Guided Radiofrequency Ablation of T1a Renal Cell Carcinoma in Korea: Mid-Term Outcomes

• Published in: Korean journal of radiology Vol. 17; no. 5; pp. 763 - 770
• Main Authors: Kim, Hae Jin, Park, Byung Kwan, Park, Jung Jae, Kim, Chan Kyo
• Format: Journal Article
• Language: English
• Published: Korea (South) The Korean Society of Radiology 01.09.2016; 대한영상의학회
• Subjects: Ablation; Adult; Aged; Aged, 80 and over; Anesthesia; Biopsy; Carcinoma, Renal Cell - diagnostic imaging; Carcinoma, Renal Cell - pathology; Carcinoma, Renal Cell - surgery; Catheter Ablation - adverse effects; Catheter Ablation - methods; Clinical outcomes; Creatinine; Disease prevention; Electrodes; Female; Genitourinary Imaging; Glomerular Filtration Rate; Humans; Intubation; Kaplan-Meier Estimate; Kidney cancer; Kidney Neoplasms - diagnostic imaging; Kidney Neoplasms - pathology; Kidney Neoplasms - surgery; Male; Medical imaging; Metastasis; Middle Aged; Patients; Radiography, Interventional - methods; Retrospective Studies; Survival analysis; Time Factors; Tomography, X-Ray Computed - methods; Treatment Outcome; Tumors; Ureteral Obstruction - etiology; 방사선과학; United States > US; Treatment outcomes; Radiofrequency catheter ablation; Computed tomography; Renal cell carcinoma
• ISSN: 1229-6929; 2005-8330; 2005-8330
• DOI: 10.3348/kjr.2016.17.5.763

To evaluate the mid-term outcomes of percutaneous radiofrequency ablation (RFA) treatment in patients with small (< 4 cm) renal cell carcinoma (RCC) in Korea. Between 2010 and 2015, 51 patients (40 men and 11 women; median age, 57 years) with biopsyproven 51 RCC were treated using CT-guided RFA. All patients were clinically staged T1aN0M0 prior to RFA. The median tumor size and follow-up period were 2.1 cm (range, 1.0-3.9 cm) and 26 months (4-60 months), respectively. Local tumor progression, distant metastasis, primary and secondary effectiveness rates, and major complication rates were recorded. Estimated glomerular filtration rates (GFRs) between pre-RFA and last follow-up were compared using paired t tests. The 2-year recurrence-free survival rate was calculated using Kaplan-Meier survival analysis. Of the 51 patients, 2 (3.9%) experienced local tumor progression, and 1 (2.0%) had lymph node metastasis after the first RFA session. Primary and secondary effectiveness rates were 96.1% (49/51) and 100% (1/1), respectively. Only 1 patient experienced a major complication (uretero-pelvic stricture) after the second RFA session for treating a local tumor progression, and the major complication rate was 1.9% (1/52). The median pre-RFA and last follow-up GFRs were 87.1 mL/ min/1.73 m(2) (14.2-142.7 mL/min/1.73 m(2)) and 72.0 mL/min/1.73 m(2) (7.2-112.6 mL/min/1.73 m(2)), respectively (p < 0.0001). The 2-year recurrence-free survival rate was 96.0%. CT-guided RFA is a safe and effective treatment in Korean patients with T1a RCC because of excellent mid-term outcomes.